Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel); Jewel P-WCD Firmware; Jewel Placement Accessory (Class
Element Science, Inc. · Decision date Mar 4, 2026
What did the FDA approve?
FDA records P230022/S003 as a supplement to PMA P230022, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Mar 4, 2026.
FDA approval order statement
approval for minor software modifications to the Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) and the optional Jewel Mobile App.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 4, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P230022/S003
- Regulatory pathway
- PMA supplement
- Applicant
- Element Science, Inc.
- Product code
- MVK
- Decision code
- APPR
- Decision date
- Mar 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Wearable automated external defibrillator.
- Applicant
- Element Science, Inc.
- Product code
- MVK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230022/S001 · Related supplement
Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel), Jewel P-WCD Firmware, Device Accessories Skin Preparati
P230022/S003 received
Application receipt date recorded by FDA.
P230022/S002 · Related supplement
Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel); Jewel P-WCD Firmware; Jewel Placement Accessory (Class
P230022/S004 · Related supplement
Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel), Jewel P-WCD Firmware, Device Accessories Skin Preparati
P230022/S006 · Related supplement
Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel), Jewel P-WCD Firmware, Device Accessories Skin Preparati
P230022/S003 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P230022. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230022
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Element Science, Inc. | PMA supplement | Aug 20, 2025 | FDA | |
| Element Science, Inc. | PMA supplement | Nov 18, 2025 | FDA | |
| Element Science, Inc. | PMA supplement | Nov 19, 2025 | FDA | |
| Element Science, Inc. | PMA supplement | Jan 13, 2026 | FDA |
Explore the linked device profile
Other records with product code MVK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Kestra Medical Technologies, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
LifeVest Wearable DefibrillatorP010030/S205 | Zoll Manufacturing Corporation | PMA supplement | Oct 6, 2026 | FDA |
LifeVest Wearable DefibrillatorP010030/S204 | Zoll Manufacturing Corporation | PMA supplement | Oct 5, 2026 | FDA |
LifeVest Wearable DefibrillatorP010030/S203 | Zoll Manufacturing Corporation | PMA supplement | Sep 29, 2026 | FDA |
| Kestra Medical Technologies, Inc. | PMA supplement | Sep 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Element Science, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 301 Chesapeake Dr., Redwood City, CA, 94063
Sources and methodology
- Original FDA record: P230022/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




